Most biotech startups fail because they chase incremental improvements. PharmEnable Therapeutics is betting on a high-risk, high-reward strategy: using AI to access the 'inaccessible' chemical space that traditional methods ignore. With just 24 employees, they are challenging the billion-dollar giants of drug discovery.

"Traditional drug discovery hits a wall at 60% of the proteome. PharmEnable is building a ladder."

The company’s tech stack reveals a modern, lean approach. They utilize Tailwind CSS and Bootstrap for rapid frontend development, likely managed by a small engineering team. The reliance on jQuery suggests some legacy code, but the inclusion of core-js and modern lazy loading indicates a focus on performance—critical for processing complex molecular data visualizations.

• Niche Focus: Specializing in small molecule therapeutics, not biologics.
• AI-First: David Vidal leads Molecular Informatics & AI, signaling algorithms over wet-lab brute force.
• Lean Operations: $2.9M revenue with 24 employees suggests high revenue per employee (RPE), typical of IP-heavy biotechs.